Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 5, Issue 2, Pages 219-228Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/EHM.12.7
Keywords
bleeding risk; comorbidity; epidemiology; incidence; ITP; prognosis
Categories
Funding
- Amgen
Ask authors/readers for more resources
Adult immune thrombocytopenia was previously considered a benign disease affecting young people and with a low risk of severe bleeding. This view was challenged by studies published during the past decade, as the median age of adult immune thrombocytopenia patients has been found to be 55-60 years and the incidence increases with age. Recent studies reported that mortality and morbidity are increased compared with the general population. In this review, we describe patient-specific factors associated with the outcome of disease, the clinical course of immune thrombocytopenia including the potential adverse impact of some treatments and finally the overall prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available